Profile data is unavailable for this security.
About the company
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
- Revenue in USD (TTM)9.30m
- Net income in USD-157.13m
- Incorporated2011
- Employees147.00
- LocationCaribou Biosciences Inc2929 7TH STREET, STE 120BERKELEY 94710United StatesUSA
- Phone+1 (510) 982-6030
- Fax+1 (302) 531-3150
- Websitehttps://www.cariboubio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVITA Medical Inc | 71.61m | -48.59m | 161.43m | 226.00 | -- | -- | -- | 2.25 | -1.75 | -1.75 | 2.57 | -0.5446 | 1.05 | 1.69 | 6.86 | 316,854.00 | -71.40 | -- | -182.42 | -- | 83.27 | -- | -67.85 | -- | 0.4557 | -8.22 | 1.63 | -- | 11.45 | -- | 21.44 | -- | -- | -- |
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 163.77m | 46.00 | -- | -- | -- | 37.20 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 165.27m | 105.00 | -- | -- | -- | 137.72 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| ProQR Therapeutics NV | 18.79m | -49.75m | 166.45m | 166.00 | -- | 2.55 | -- | 8.86 | -0.4785 | -0.4785 | 0.1809 | 0.6192 | 0.139 | -- | 9.70 | 113,167.00 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Microbot Medical Inc | 0.00 | -13.07m | 166.55m | 21.00 | -- | 2.09 | -- | -- | -0.4513 | -0.4513 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -30.06 | -67.69 | -31.62 | -80.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -35.03 | -- |
| MDxHealth SA | 103.07m | -31.43m | 166.81m | 312.00 | -- | -- | -- | 1.62 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Jyong Biotech Ltd | 0.00 | -2.95m | 167.26m | 29.00 | -- | -- | -- | -- | -0.0397 | -0.0397 | 0.00 | -0.3027 | 0.00 | -- | -- | 0.00 | -13.35 | -- | -127.41 | -- | -- | -- | -- | -- | -- | -1.96 | 2.79 | -- | -- | -- | 31.39 | -- | -- | -- |
| Prelude Therapeutics Inc | 10.50m | -111.77m | 170.36m | 131.00 | -- | 2.62 | -- | 16.23 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 171.98m | 147.00 | -- | 1.21 | -- | 18.50 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| Fate Therapeutics Inc | 6.65m | -136.32m | 174.40m | 161.00 | -- | 0.8352 | -- | 26.24 | -1.15 | -1.15 | 0.056 | 1.80 | 0.0175 | -- | 2.58 | 41,279.50 | -35.89 | -32.10 | -39.80 | -36.05 | -- | -- | -2,051.08 | -414.22 | -- | -- | 0.00 | -- | -51.24 | -26.71 | 26.82 | -- | 3.83 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 180.63m | 166.00 | -- | 0.7142 | -- | 6.72 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 186.02m | 14.00 | -- | 1.56 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 186.63m | 105.00 | -- | 6.65 | -- | 1.26 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 187.58m | 8.00 | -- | 19.24 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
Data as of Mar 03 2026. Currency figures normalised to Caribou Biosciences Inc's reporting currency: US Dollar USD
19.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.75m | 4.02% |
| Kynam Capital Management LPas of 31 Dec 2025 | 2.50m | 2.68% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 2.06m | 2.21% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 31 Dec 2025 | 2.00m | 2.14% |
| J. Lamarck Asset Management SAas of 30 Jan 2026 | 1.65m | 1.77% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 1.64m | 1.75% |
| abrdn, Inc.as of 31 Dec 2025 | 1.39m | 1.49% |
| Two Sigma Advisers LPas of 31 Dec 2025 | 1.12m | 1.19% |
| Two Sigma Investments LPas of 31 Dec 2025 | 1.02m | 1.09% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 981.89k | 1.05% |
More ▼
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
